4/18-4/19

On April 18, 2024, the anticipated first XDC New Drug Conference kicked off, with Glotope hosting the "Comprehensive Nuclear Medicine Development Lecture Hall" as one of the event's highlights. The audience was highly engaged. Numerous industry experts participated, uncovering high-potential targets in nuclear medicine research, sharing updates on the radiopharmaceutical industry and regulations, and discussing full lifecycle strategies for radiopharmaceutical development. The goal was to provide professional solutions to common challenges in the nuclear medicine industry and accelerate the advancement of high-potential radiopharmaceutical projects.

At the Nuclear Medicine Lecture Hall, industry experts including Dr. Shen Di, Head of Innovation at Glotope; Dr. Xu Jianfeng, CMC Director at Glotope; Dr. Fu Peng, Assistant President of Beijing Saffron Pharmaceutical Research Institute; Liu Shuang, Senior Vice President of Sinotau Pharmaceuticals; and Dr. Geng Xueli, Executive General Manager of SDIC Venture Capital, discussed radiopharmaceutical targets, CMC, pre-clinical evaluation strategies, and registration practices. They also engaged in interactive discussions with attendees.

Comprehensive Nuclear Medicine Development Workshop

Dr. Shen Di, Head of Innovation at Glotope, presented about the latest developments in radiopharmaceuticals, highlighting therapeutic and diagnostic targets, current research status, commercial prospects, and development challenges. She recommended several high-potential projects, offering valuable opportunities for companies interested in the nuclear medicine field.

Comprehensive Analysis of Radiopharmaceutical CMC

Dr. Xu Jianfeng, CMC Director at Glotope, led the "Comprehensive Analysis of Radiopharmaceutical CMC" session. She thoroughly explained the unique aspects of radiopharmaceutical CMC, provided an in-depth interpretation of current CMC technical requirements in China, and analyzed CMC strategies. Dr. Xu detailed key research points, execution plans, and the quality management system for CMC.

Analysis of Pre-Clinical Evaluation Strategies for RDC

Dr. Fu Peng, Biopharmaceutical Industry Review Expert for the Shenzhen Development and Reform Commission and Assistant President of Beijing Saffron Pharmaceutical Research Institute, led the session "Analysis of Non-Clinical Evaluation Strategies for RDC." He summarized the basis for non-clinical evaluation of radiopharmaceuticals and compared the similarities and differences between ADC and RDC in pre-clinical evaluation strategies. Dr. Fu elaborated on key considerations for First-In-Human (FIH) research of radiopharmaceuticals using case studies.

The Path for Radiopharmaceutical Registration

Insights on the Radiopharmaceutical Sector from an Investment Perspective

Dr. Geng Xueli, Executive General Manager of SDIC Venture Capital, led the session "Insights on the Radiopharmaceutical Sector from an Investment Perspective." She analyzed the development prospects of radiopharmaceuticals and the unique characteristics of China's radiopharmaceutical industry from an investment standpoint. Her insights on "Investment Logic in Radiopharmaceuticals" provided industry professionals with a clear direction for the sector's growth.

Nuclear Medicine Full Process Development (Workshop) The venue was packed with people

Embracing the Nuclear Medicine Subforum

In addition to the exciting nuclear medicine workshop hosted by Glotope on the morning of April 18, COO Bai Ge presented "New Models and Case Analysis of Innovative Radiopharmaceutical R&D and Commercialization" in the afternoon. He summarized the fundamental strategies for introducing and exporting innovative radiopharmaceuticals and shared practical experiences with case studies from disease states such as Alzheimer's disease and oncology.

Nuclear Medicine Upstream and Downstream Industry Chain Subforum

On the afternoon of April 19, Wang Song, Quality Director at Glotope, delivered an insightful presentation on "Differences in Domestic and International Radiopharmaceutical Manufacturing Regulations." He provided an overview of domestic and international radiopharmaceutical regulatory frameworks and detailed the regulatory systems of overseas agencies. By comparing the regulations, Wang discussed future trends in radiopharmaceutical regulation and offered practical recommendations.

Glotope looks forward to having more opportunities in the future to discuss cutting-edge knowledge in the radiopharmaceutical field with clients and share the achievements of industry development. We also welcome communication and exchanges with industry peers. Glotope is eager to work with you to drive the radiopharmaceutical industry forward.